4.7 Review

Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

期刊

KIDNEY INTERNATIONAL
卷 91, 期 3, 页码 539-551

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.kint.2016.10.005

关键词

anti-complement therapies; atypical hemolytic uremic syndrome; C3 glomerulopathy; complement; glomerulonephritis; kidney disease

资金

  1. Akari Therapeutics
  2. Alexion
  3. Achillion
  4. Fight for Sight
  5. Kidney Research UK
  6. Macular Society
  7. Medical Research Council
  8. Northern Counties Kidney Research Fund
  9. Wellcome Trust
  10. Novartis
  11. CSL Behring
  12. Kidney Disease: Improving Global Outcomes (KDIGO)
  13. Achillion Pharmaceuticals
  14. Alexion Pharmaceuticals
  15. Omeros
  16. Academy of Medical Sciences (AMS) [AMS-SGCL5-Gale] Funding Source: researchfish

向作者/读者索取更多资源

In both atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathy (C3G) complement plays a primary role in disease pathogenesis. Herein we report the outcome of a 2015 Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference where key issues in the management of these 2 diseases were considered by a global panel of experts. Areas addressed included renal pathology, clinical phenotype and assessment, genetic drivers of disease, acquired drivers of disease, and treatment strategies. In order to help guide clinicians who are caring for such patients, recommendations for best treatment strategies were discussed at length, providing the evidence base underpinning current treatment options. Knowledge gaps were identified and a prioritized research agenda was proposed to resolve outstanding controversial issues.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据